PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 29932878-0 2018 COX-2 inhibition by celecoxib in epithelial ovarian cancer attenuates E-cadherin suppression through reduced Snail nuclear translocation. Celecoxib 20-29 cadherin 1 Homo sapiens 70-80 29932878-5 2018 Depletion of COX-2, by celecoxib treatment, resulted in attenuated nuclear translocation of Snail, and, in turn, significantly increased E-cadherin in EOC cell line SKOV3, which was established to be due to the reduced binding of Snail onto E-cadherin promoter. Celecoxib 23-32 cadherin 1 Homo sapiens 137-147 28053596-8 2017 RESULTS: MDR1, MRP1, BCRP and Trkb, E-cadherin, beta-catenin were significantly downregulated in cells treated with the combination of celecoxib and cisplatin, and decreased beta-catenin level was found in cells with wortmannin, a specific PI3K inhibitor. Celecoxib 135-144 cadherin 1 Homo sapiens 36-46 24887090-4 2014 METHODS: We used quantitative real-time PCR to examine the effects of three selective Cox-2 inhibitors, i.e., celecoxib, NS-398, and SC-791 on the gene expressions of E-cadherin (CDH-1) and its transcriptional repressors (SIP1, Snail, Twist) in the human HNSCC cell lines HSC-2 and HSC-4. Celecoxib 110-119 cadherin 1 Homo sapiens 167-177 27528025-5 2016 We demonstrated that celecoxib and sulindac were effective in preventing TGF-beta1-induced EMT, as indicated by upregulation of the epithelial marker, E-cadherin, and downregulation of mesenchymal markers and transcription factors. Celecoxib 21-30 cadherin 1 Homo sapiens 151-161 25424898-9 2015 However, ZEB1 siRNA reversed Celecoxib-induced E-cadherin expression and N-cadherin expression, as well as cellular invasiveness. Celecoxib 29-38 cadherin 1 Homo sapiens 47-57 21215211-7 2010 Immunocytochemistry showed that celecoxib significantly induced the increase of E-cadherin protein expression, also with a dose-dependence in 0 micromol/L, 25 micromol/L, 50 micromol/L group was (21.7 +- 2.6), (28.7 +- 2.4), (40.3 +- 1.3), and 50 micromol/L group increased significantly (F = 78.637, P < 0.01). Celecoxib 32-41 cadherin 1 Homo sapiens 80-90 21882253-5 2012 Interestingly, celecoxib prevented EMT-related changes, as shown by modifications of beta-catenin intracellular localization or vimentin and E-cadherin levels, as well as HT-29 invasiveness induced by hypoxia, EGF, or hypoxia plus EGF. Celecoxib 15-24 cadherin 1 Homo sapiens 141-151 24115825-11 2013 Treatment of SGC-7901 cells with celecoxib led to a reduced expression of Snail but an increased expression of E-cadherin. Celecoxib 33-42 cadherin 1 Homo sapiens 111-121 24115825-13 2013 However, siRNA-mediated knockdown of NF-kappaB partially abolished the effect of celecoxib and PGE2 on the regulation of E-cadherin and Snail in SGC-7901 cells. Celecoxib 81-90 cadherin 1 Homo sapiens 121-131 23670240-9 2013 Treatment of the SGC7901 cells (which express high levels of COX-2) with celecoxib, a COX-2 inhibitor, not only led to a marked dose- and time-dependent decrease in the expression of COX-2, NF-kappaB and Snail, but also led to a significant increase in the expression of E-cadherin, and this was associated with a reduction in cell invasion. Celecoxib 73-82 cadherin 1 Homo sapiens 271-281 21215211-8 2010 RT-PCR showed that celecoxib reduced the expression of Cox-2 mRNA expression in 25, 50 micromol/L group decreased significantly compared with the control group (respectively, t were 23.950 and 36.651, P < 0.01), but it enhanced the expression of E-cadherin mRNA expression in 25, 50 micromol/L group was significantly higher (respectively, t were 35.829 and 81.497, P < 0.01). Celecoxib 19-28 cadherin 1 Homo sapiens 249-259 21215211-9 2010 CONCLUSION: Celecoxib can inhibits the invasive ability of NPC cell line CNE-2Z, which possibly relates with the upregulated expression of E-cadherin. Celecoxib 12-21 cadherin 1 Homo sapiens 139-149 18303430-0 2008 Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin. Celecoxib 30-39 cadherin 1 Homo sapiens 184-194 19622294-0 2009 [Short-term preoperative treatment of celecoxib, a selective cyclooxygenase-2 inhibitor, on E-cadherin expression in gastric carcinoma tissues]. Celecoxib 38-47 cadherin 1 Homo sapiens 92-102 19622294-2 2009 This study was to investigate the effect of celecoxib, a selective COX-2 inhibitor, on the expression of E-cadherin and serum levels of soluble E-cadherin in gastric carcinomas. Celecoxib 44-53 cadherin 1 Homo sapiens 105-115 19622294-2 2009 This study was to investigate the effect of celecoxib, a selective COX-2 inhibitor, on the expression of E-cadherin and serum levels of soluble E-cadherin in gastric carcinomas. Celecoxib 44-53 cadherin 1 Homo sapiens 144-154 19622294-8 2009 RESULTS: Compared to the surgery group, the expression of COX-2 was significantly lower while that of E-cadherin was significantly higher in celecoxib plus surgery group. Celecoxib 141-150 cadherin 1 Homo sapiens 102-112 19622294-9 2009 The concentrations of serum soluble E-cadherin before treatment were significantly higher in the surgery [(53.47+/-9.62) ng/mL] and the celecoxib plus surgery [(51.57+/-9.79) ng/mL] groups than in the control group [(37.17+/-5.38) ng/ml] (P<0.01). Celecoxib 136-145 cadherin 1 Homo sapiens 36-46 19622294-11 2009 The soluble E-cadherin level on the sixth day [(44.11+/-8.36) ng/mL] was significantly lower than that before treatment in the celecoxib plus surgery group (P<0.01). Celecoxib 127-136 cadherin 1 Homo sapiens 12-22 19622294-12 2009 CONCLUSION: Short-term preoperative treatment of celecoxib up-regulates the expression of E-cadherin in gastric carcinomas. Celecoxib 49-58 cadherin 1 Homo sapiens 90-100 19940363-5 2009 RESULTS: Down-regulation of COX-2 by celecoxib led to up-regulation of E-cadherin mRNA and protein levels in conventional gastric cancer cell lines, whereas expression was down regulated in the early-onset gastric cancer (EOGC) cell line. Celecoxib 37-46 cadherin 1 Homo sapiens 71-81 17224647-5 2007 In our study we investigate the effect of Celecoxib on expression of E-cadherin and serum soluble E-cadherin, as well as on apoptosis and angiogenesis in patients with gastric cancer. Celecoxib 42-51 cadherin 1 Homo sapiens 69-79 17224647-11 2007 Significantly decreased expression of COX-2, increased E-cadherin and apoptosis, decreased VEGF and MVD were observed in gastric cancer tissues from patients receiving Celecoxib compared to Surgery group. Celecoxib 168-177 cadherin 1 Homo sapiens 55-65 17224647-5 2007 In our study we investigate the effect of Celecoxib on expression of E-cadherin and serum soluble E-cadherin, as well as on apoptosis and angiogenesis in patients with gastric cancer. Celecoxib 42-51 cadherin 1 Homo sapiens 98-108 35176901-9 2022 In addition, celecoxib potentiated the MLN4924-induced EMT, decreased the expression of N-cadherin and vimentin, and activated the expression of E-cadherin. Celecoxib 13-22 cadherin 1 Homo sapiens 145-155 31114336-11 2019 Celecoxib up-regulated E-cadherin protein through inhibiting COX-2-prostaglandin E2 (PGE2)-PGE2 receptor 2 (EP2)-p-Akt/p-ERK signaling pathway to suppress HCC cells migration and invasion. Celecoxib 0-9 cadherin 1 Homo sapiens 23-33 32269737-4 2020 The present study found that both the Cox-2 inhibitor celecoxib and the EP2 antagonist PF-04418948 upregulated CDH-1 expression, restored membranous localization of E-cadherin, and reduced vimentin expression, by downregulating the transcriptional repressors of E-cadherin in BICR6 and FaDu cells. Celecoxib 54-63 cadherin 1 Homo sapiens 111-116 32269737-4 2020 The present study found that both the Cox-2 inhibitor celecoxib and the EP2 antagonist PF-04418948 upregulated CDH-1 expression, restored membranous localization of E-cadherin, and reduced vimentin expression, by downregulating the transcriptional repressors of E-cadherin in BICR6 and FaDu cells. Celecoxib 54-63 cadherin 1 Homo sapiens 165-175 32269737-4 2020 The present study found that both the Cox-2 inhibitor celecoxib and the EP2 antagonist PF-04418948 upregulated CDH-1 expression, restored membranous localization of E-cadherin, and reduced vimentin expression, by downregulating the transcriptional repressors of E-cadherin in BICR6 and FaDu cells. Celecoxib 54-63 cadherin 1 Homo sapiens 262-272